NZ334998A - Use of an agonist or antagonist for inhibiting the expression of a C140 receptor - Google Patents

Use of an agonist or antagonist for inhibiting the expression of a C140 receptor

Info

Publication number
NZ334998A
NZ334998A NZ334998A NZ33499896A NZ334998A NZ 334998 A NZ334998 A NZ 334998A NZ 334998 A NZ334998 A NZ 334998A NZ 33499896 A NZ33499896 A NZ 33499896A NZ 334998 A NZ334998 A NZ 334998A
Authority
NZ
New Zealand
Prior art keywords
agonist
absent
amino acid
receptor
expression
Prior art date
Application number
NZ334998A
Other languages
English (en)
Inventor
Johan Sundelin
Robert M Scarborough
Original Assignee
Cor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cor Therapeutics Inc filed Critical Cor Therapeutics Inc
Publication of NZ334998A publication Critical patent/NZ334998A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ334998A 1995-01-25 1996-01-25 Use of an agonist or antagonist for inhibiting the expression of a C140 receptor NZ334998A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39030195A 1995-01-25 1995-01-25

Publications (1)

Publication Number Publication Date
NZ334998A true NZ334998A (en) 2000-11-24

Family

ID=23541929

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ302524A NZ302524A (en) 1995-01-25 1996-01-25 Dna encoding the c140 receptor, agonists and antagonists therefor and use in assays to detect vascular pressure abnormalities
NZ334998A NZ334998A (en) 1995-01-25 1996-01-25 Use of an agonist or antagonist for inhibiting the expression of a C140 receptor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ302524A NZ302524A (en) 1995-01-25 1996-01-25 Dna encoding the c140 receptor, agonists and antagonists therefor and use in assays to detect vascular pressure abnormalities

Country Status (7)

Country Link
EP (1) EP0870198A4 (xx)
JP (1) JPH11514207A (xx)
KR (1) KR19980701637A (xx)
CA (1) CA2211176A1 (xx)
NO (1) NO973422L (xx)
NZ (2) NZ302524A (xx)
WO (1) WO1996023225A1 (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9620028D0 (en) 1996-09-26 1996-11-13 Ludwig Inst Cancer Res Factors which interact with oncoproteins
US6737252B2 (en) 1997-07-25 2004-05-18 Schering Corporation 7 transmembrane receptor family member BLRX
CA2689373A1 (en) 1998-09-17 2000-03-30 Hopital Sainte-Justine G protein-coupled receptor antagonists
US6984719B1 (en) 1998-09-17 2006-01-10 Hospital Sainte-Justine Peptide antagonists of prostaglandin F2α receptor
WO2001042281A1 (en) 1999-12-06 2001-06-14 Hôpital Sainte-Justine Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis
US7214655B2 (en) * 2001-05-21 2007-05-08 Johnson & Johnson Consumer Companies, Inc. Peptides and the use thereof in darkening the skin
US7521530B2 (en) 2002-06-11 2009-04-21 Universite De Montreal Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F2α receptor
US7910556B2 (en) 2004-12-28 2011-03-22 Kowa Company, Ltd. PAR-2 agonist
EP1864994B1 (en) 2005-03-29 2011-10-26 Kowa Company, Ltd. Par-2 agonist
FR2883873B1 (fr) * 2005-03-31 2009-07-10 Pharmamens Sarl Inhibiteurs d'age
AR070911A1 (es) * 2008-03-19 2010-05-12 Regeneron Pharma Uso de antagonistas del receptor par2 activado con proteasa

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629174A (en) * 1993-07-26 1997-05-13 Cor Therapeutics, Inc. Recombinant C140 receptor

Also Published As

Publication number Publication date
WO1996023225A1 (en) 1996-08-01
EP0870198A4 (en) 2001-04-04
NO973422D0 (no) 1997-07-24
JPH11514207A (ja) 1999-12-07
NZ302524A (en) 1999-05-28
EP0870198A1 (en) 1998-10-14
NO973422L (no) 1997-09-24
CA2211176A1 (en) 1996-08-01
KR19980701637A (ko) 1998-06-25

Similar Documents

Publication Publication Date Title
NZ334998A (en) Use of an agonist or antagonist for inhibiting the expression of a C140 receptor
PT883687E (pt) Receptores de quimiocinas c-c, ckr-5, cc, os seus derivados e as suas utilizacoes
Bowers et al. Structure-activity relationships of a synthetic pentapeptide that specifically releases growth hormone in vitro
AU6691498A (en) Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase
FI842166A (fi) Bukspottskoertelns grf hos maenniskan.
AU1756297A (en) Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
WO1992007830A3 (en) Oxindole peptide antagonists
EA199800116A1 (ru) Пирролопиримидины и фармацевтические композиции, включающие эти соединения
Ljungqvist et al. Design, synthesis and bioassays of antagonists of LHRH which have high antiovulatory activity and release negligible histamine
ATE404583T1 (de) Funktionelle antagonisten von hedgehog-aktivität
DE59903410D1 (de) Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
MY110217A (en) Use of l-deprenyl for retarding deterioration due to aging in dogs
EP0212903A3 (en) Polypeptide derivatives containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues
EP1320541A4 (en) TGF-BETA INHIBITORS AND METHODS
BR0007864A (pt) Composto, e, uso de um composto
DE69009476D1 (de) Hemmung des reaktionswegs für die n-ende-regel in lebenden zellen.
SE9300012D0 (sv) New peptides
ATE426028T1 (de) Zellvolumenregulierte humane kinase h-sgk
Yoo et al. Conversion of lysine 91 to methionine or glutamic acid in human choriogonadotropin alpha results in the loss of cAMP inducibility.
BR9909006A (pt) Processo de preparar uma alimentação animal, planta transgênica, construção de expressão, vetor, e, processo de preparar uma planta transgênica
TR199700261A2 (xx) Yeni Pirimido (1,2-a) indoller.
DE69311873D1 (de) Fed-batch-Verfahren für Proteine sekretierende Zellen
TR199802659T2 (xx) Topikal akne tedavisi i�in bir ara� ve tedavi y�ntemi.
Amr et al. Sialic acid residues of the α-subunit are required for the thyrotropic activity of hog
TR199902866T2 (xx) Organo- koruyucu aktiviteye sahip yeni BPC peptid tuzlar�, haz�rlanmalar� ve terapide kullan�lmalar� i�in prosesler.